Frontier Biotechnologies Inc. (SHA:688221)

Market Cap	3.21B
Revenue (ttm)	129.47M
Net Income (ttm)	-201.52M
Shares Out	374.58M
EPS (ttm)	-0.54
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,899,688
Average Volume	3,535,636
Open	8.63
Previous Close	8.64
Day's Range	8.50 - 8.67
52-Week Range	4.48 - 10.71
Beta	0.76
RSI	44.49
Earnings Date	Apr 30, 2025

About Frontier Biotechnologies

Frontier Biotechnologies Inc., a commercial-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes various medicines that improve patient health. The company’s medicines address the unmet medical needs of patients in the areas of anti-HIV treatment and pain management. It offers Aikening, a long-acting HIV fusion inhibitor for the treatment of HIV infection and AIDS. The company’s products in development include FB1002, an all-injectable long-acting HIV therapy; FB2001, a SARS-CoV-2 3CL protease inhibitor under c...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2013
• Employees: 395
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688221

Financial Performance

In 2024, Frontier Biotechnologies's revenue was 129.47 million, an increase of 13.32% compared to the previous year's 114.25 million. Losses were -201.52 million, -38.74% less than in 2023.